Table 1 Demographic and clinical features of migraine patients by high-frequency episodic (HFEM) or chronic migraine (CM)
Number (%) or mean ± SD | P-value | |||
|---|---|---|---|---|
All | HFEM | CM | ||
Patients | 864 | 208 (24.1) | 656 (75.9) | |
Age, yrs | 47.8 ± 11.5 | 48.2 ± 11.0 | 47.7 ± 11.6 | 0.629 |
Females | 675 (78.1) | 158 (76.0) | 517 (78.8) | 0.388 |
BMI | 23.2 ± 3.7 | 22.7 ± 2.7 | 23.3 ± 3.9 | 0.069 |
BMI class | 0.032 | |||
Underweight | 42 (5.8) | 8 (4.6) | 34 (6.1) | |
Normal | 504 (68.9) | 126 (73.3) | 378 (67.6) | |
Overweigh | 152 (20.8) | 37 (21.5) | 115 (20.6) | |
Obesity | 33 (4.5) | 1 (0.6) | 32 (5.7) | |
Disease duration, yrs | 30.3 ± 12.6 | 29.5 ± 12.3 | 30.6 ± 12.7 | 0.305 |
MMDs/MHDs at baseline | 20.6 ± 7.5 | 10.9 ± 2.0 | 23.7 ± 5.8 | – |
MOH | – | 571 (87.0) | – | |
MOH duration | – | 9.1 ± 8.9 | – | |
Monthly analgesic intake at baseline | 23.8 ± 21.2 | 12.6 ± 5.5 | 27.4 ± 23.0 | < 0.001 |
NRS score | 7.7 ± 1.3 | 7.5 ± 1.4 | 7.8 ± 1.3 | 0.005 |
UP | 418 (49.5) | 117 (58.2) | 301 (46.8) | 0.005 |
Pain quality | 0.286 | |||
Pulsating | 556 (67.2) | 127 (64.8) | 429 (68.0) | |
Pressing/tightening | 243 (29.4) | 59 (30.1) | 184 (29.2) | |
Other | 28 (3.4) | 10 (5.1) | 18 (2.8) | |
UAs | 406 (48.6) | 80 (39.8) | 326 (51.4) | 0.004 |
Allodynia | 472 (56.2) | 89 (44.2) | 383 (59.9) | < 0.001 |
Dopaminergic symptoms | 563 (67.5) | 146 (72.6) | 417 (65.9) | 0.075 |
UP + allodynia | 261 (58.0) | 55 (53.9) | 206 (59.1) | 0.343 |
UP + UAs | 248 (55.4) | 54 (53.5) | 194 (55.9) | 0.664 |
UP + UAs + allodynia | 221 (64.6) | 47 (59.5) | 174 (66.2) | 0.277 |
Triptan responders | 512 (63.8) | 139 (70.2) | 373 (61.7) | 0.036 |
Concomitant prophylaxis | 464 (56.0) | 105 (50.5) | 359 (54.7) | 0.322 |
Prior treatment failures | 4.9 ± 2.3 | 4.1 ± 2.2 | 5.2 ± 2.3 | < 0.001 |
BoNT/A respondersa | 38 (10.3) | 15 (23.1) | 23 (7.5) | < 0.001 |
≥ 1 comorbidity | 401 (46.4) | 102 (49.0) | 299 (45.5) | 0.428 |
Psychiatric comorbidities | 174 (20.5) | 28 (13.9) | 146 (22.6) | 0.007 |
HIT-6 score | 66.0 ± 9.2 | 65.1 ± 6.6 | 66.2 ± 9.9 | 0.133 |
Erenumab | 639 (74.0) | 169 (81.2) | 470 (71.6) | |
Galcanezumab | 173 (20.0) | 28 (13.5) | 145 (22.1) | |
Fremanezumab | 52 (6.0) | 11 (5.3) | 41 (6.3) | |
Monthly regimen | 43 (5.0) | 7 (3.4) | 36 (5.5) | |
Quaterly regimen | 9 (1.0) | 4 (1.9) | 5 (0.8) | |